[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pruritus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pruritus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,71,96,120,146,167,188,227,248,270,296,320,350,370,395,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100491375","establishment-of-a-patient-library-in-patients-with-pruritus-sine-materia-100491375",false,"NCT05678309","Establishment of a Patient Library in Patients With Pruritus Sine Materia","PRURITHEQUE","Inclusion Criteria:\n\n* Diagnosis of pruritus sine materia\n* Collection of consent\n* Adult\n\nExclusion Criteria:\n\n\\- Refusal to participate in the study","ALL","18 Years","99 Years",{"count":20,"type":21},175,"ESTIMATED","5 Years","OBSERVATIONAL","Very little is currently known about the pathophysiology of pruritus sine materia according to the etiology. The creation of this cohort should make it possible to improve our clinical and biological knowledge according to the etiology, by collecting blood, skin, feces, and clinical data.",[26,27,28],"Pruritus","Chronic Pruritus","Itch","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2023-06-16",{"date":37,"type":21},"2033-06",{"name":39,"class":40},"University Hospital, Brest","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100561686","phase-2-safety-and-tolerability-of-difelikefalin-in-adolescents-on-haemodialysis-with-moderate-to-severe-pruritus-100561686","NCT06593392","Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","KOR-PED-202 An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis With Moderate-to-Severe Pruritus","Inclusion Criteria:\n\n* 1\\. Participant must be ≥12 to \\\u003C18 years of age at the time of informed consent.\n* 2\\. Participants with CKD on HD 3 times weekly for at least 12 weeks prior to the informed consent procedure who can continue HD without changing its frequency or method.\n* 3\\. Participants whose WI-NRS score in the 7-day run-in period (meets both of the below:\n* a) WI-NRS scores have been recorded for at least 4 days through a 7-day run-in period.\n* b) The mean value of the recorded WI-NRS scores is \\>4.0\n* 4\\. Over the last 3 months prior to screening, the participant has had at least 1 of the following:\n* a) At least 2 single-pool Kt\u002FV measurements ≥1.2 on different dialysis days\n* b) At least 2 urea reduction ratio measurements ≥65% on different dialysis days\n* c) 1 single-pool Kt\u002FV measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis day\n* 5\\. Prescription dry body weight ≥20 kg\n* 6\\. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* 7\\. Participant and\u002For legal guardian (as required) is capable of providing the appropriate signed informed consent and where appropriate, assent.\n\nExclusion Criteria:\n\n* 1\\. Known to be non-compliant with HD treatments and deemed unlikely by the Investigator to complete the study\n* 2\\. Planned to receive a kidney transplant during the study. Note: being listed on a kidney transplant list is not an exclusion criterion.\n* 3\\. Participants with itching caused by conditions other than chronic renal failure or complications of chronic renal failure, which could in the opinion of the Investigator affect the efficacy evaluation (e.g., atopic dermatitis, chronic urticaria).\n* 4\\. Participants with localised itch restricted to the palms of the hands.\n* 5\\. Participants with pruritus only during the dialysis session (by participant report).\n* 6\\. Participants with known concurrent hepatic cirrhosis or severe hepatic impairment (e.g., Child-Pugh Class C).\n* 7\\. Significant systolic or diastolic heart failure (e.g., New York Heart Association Class IV congestive heart failure).\n* 8\\. Participants with concurrent malignancy except excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ that has been excised or resected completely.\n* 9\\. Severe mental illness or cognitive impairment (e.g., dementia) or other concurrent mental disorder that, in the opinion of the Investigator, would compromise the validity of study measurements.\n* 10\\. Conditions associated with clinically important disruptions to the blood brain barrier (for example, primary brain malignancies, CNS metastases or other inflammatory conditions, active multiple sclerosis, advanced Alzheimer's disease) that in the Investigator's opinion may be associated with unacceptable risk for CNS effects.\n* 11\\. Acute or unstable medical condition(s) that in the Investigator's opinion, may be associated with increased risk to the participant, or may interfere with study assessments, outcomes, or the ability to provide written informed consent or comply with study procedures.\n* 12\\. Participant is receiving ongoing ultraviolet B treatment and anticipates receiving such treatment during the study.\n* 13\\. New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening.\n* 14\\. New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening.\n* 15\\. Participant is receiving prohibited medication (e.g., nalfurafine hydrochloride, opioid antagonists) that cannot be stopped at least 14 days before enrolment in the study.\n* 16\\. Participant has known hypersensitivity to the study intervention or any components of the difelikefalin formulation.\n* 17\\. Known or suspected history of alcohol, narcotic, or other drug abuse or substance dependence within 12 months prior to screening or participant with any alcoholic beverage intake of more than two units per day more than once per week.\n* 18\\. Participation in any other investigational device or drug study \\\u003C30 days prior to screening, or current treatment with other investigational agent(s).\n* 19\\. Serum ALT, AST greater than 3× the reference ULN.","12 Years",{"count":51,"type":21},18,"INTERVENTIONAL",[54],"PHASE2","Rationale:\n\n* People with long term kidney disease who are on haemodialysis (a procedure for removing waste products from the blood) commonly develop a condition that makes their skin very itchy.\n* Difelikefalin is a medicine that can treat the itching related to long term kidney disease.\n* Clinical studies have shown difelikefalin to reduce itching in adults on haemodialysis, while being safe and tolerable.\n* The current study is being done in adolescents aged 12 to 17 years on haemodialysis who have moderate to severe itching related to long term kidney disease to assess if difelikefalin is safe in this age group.\n\nThe aims of the study are:\n\nMain aim: To assess the safety of difelikefalin in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nSecondary aim: To measure the amount of difelikefalin that enters the blood in adolescents who are on haemodialysis and have itching related to long term kidney disease\n\nStudy Design At least 18 adolescents, aged 12 to 17 years, who are on haemodialysis and have itching related to long term kidney disease will take part in this study.\n\nAll study participants will receive difelikefalin 3 (or up to 4) times weekly for up to 12 weeks. The study duration for a participant is up to 17 to 18 weeks; during this period, participants will visit the clinic 3 times weekly (during their haemodialysis visits).",[26,57],"Chronic Kidney Diseases",[59],"Chronic kidney disease associated pruritus","2026-06-10",{"date":62,"type":33},"2026-06-11",{"date":64,"type":21},"2026-06-17",{"date":66,"type":21},"2029-08-15",{"name":68,"class":69},"Vifor Fresenius Medical Care Renal Pharma","INDUSTRY",16,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100549536","phase-2-efficacy-and-tolerance-of-thc-25-cbd-25-in-patients-with-severe-pruritus-a-multicenter-double-blind-randomized-placebo-controlled-study-100549536","NCT06435299","Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study","CANNA-ITCH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Severe pruritus, defined by a mean WI-NRS score ≥7\u002F10 (evaluated on one week before inclusion, regardless of the cause of the pruritus\n* Insufficient relief (WI-NRS ≥7\u002F10 ) or poor tolerance (adverse effects) of accessible drug and non-drug therapies\n* Stable treatment (for treatment of the prurit) for at least 6 weeks\n* Affiliated or benefiting of a social security\n* Informed consent (personally dated and) signed by the participant or any representatives (impartial witness\u002Ftrusted person)\n\nExclusion Criteria:\n\n* Patients unable to consent.\n* Patients refusing to participate in research.\n* Patients under guardianship or conservatorship.\n* Personal history of psychotic disorders.\n* Severe hepatic impairment, defined as prothrombin level \\\u003C50% or with predictive biological impairment.\n* Moderate to severe renal impairment, with an estimated glomerular filtration rate ≤ 44 mL\u002Fmin\u002F1.73 m².\n* Severe cardiovascular or cerebrovascular disease, including history of myocardial infarction or stroke.\n* Pregnant or breastfeeding women.\n* Lack of understanding of questionnaires or inability to follow up.\n* Women of childbearing potential unwilling to use appropriate contraception.\n* Cannabinoid use outside the clinical trial\n* Use of cannabis or its derivatives less than one week before inclusion\n* History of hypersensitivity or allergy to any cannabinoid product.\n* Allergy to nuts.",{"count":79,"type":21},218,[54],"Chronic pruritus affects 10-20% of the population and causes a major reduction in quality of life, comparable to pain, with significant psychological, social, and functional consequences. Current treatments are often insufficient, highlighting the urgent need for new therapeutic options.\n\nRecent advances in the pathophysiology of itch have shown the involvement of the endocannabinoid system (CB1, CB2, and TRPV1 receptors) in modulating itch signal transmission and cutaneous inflammation. Cannabinoids, particularly the balanced CBD:THC combination, appear promising as they provide both central and peripheral antipruritic effects, while CBD helps mitigate the psychotropic side effects of THC.\n\nPreclinical studies and limited clinical data suggest efficacy across various forms of pruritus (dermatological, uremic, cholestatic), though robust controlled trials are still lacking. Evidence from nabiximols (1:1 CBD:THC spray) in other conditions such as neuropathic pain and spasticity further supports the rationale for this approach.\n\nTherefore, sublingual LGP THC25:CBD25 oil has been selected for its balanced ratio, simple administration route, and expected tolerability, to evaluate its efficacy and safety in the treatment of chronic pruritus.",[26],[84,85,86],"itching","THC","CBD","NOT_YET_RECRUITING",{"date":89,"type":33},"2026-06-12",{"date":91,"type":21},"2027-01-01",{"date":93,"type":21},"2029-03-01",{"name":39,"class":40},6,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":52,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100459483","phase-3-efficacy-and-safety-of-subcutaneous-dupilumab-for-the-treatment-of-adult-participants-with-chronic-pruritus-of-unknown-origin-cpuo-liberty-cpuo-chic-100459483","NCT05263206","Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)","Inclusion Criteria:\n\n* Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 90 years of age inclusive, at the time of signing the informed consent.\n* Participants with chronic pruritus for at least 6 months before the screening visit.\n* Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (excluding chronic pruritus secondary to dermatological or systemic conditions, of neuropathic or psychogenic origin or secondary to drugs).\n* Chronic pruritus must affect at least 2 of the following body areas: legs, arms, or trunk.\n* History of insufficient control of the chronic pruritus with prior treatment.\n* Participants should receive optimal treatment for concomitant conditions that could impact pruritus (eg, diabetes, iron deficiency).\n* Participants must have a history of severe itch and a worst itch score of ≥7 at screening on the WI-NRS (score scale ranges from 0 to 10; higher score indicates worse itch) and Patient Global Impression of Severity (PGIS) of pruritus scored \"severe\" at screening.\n* Participants must have an average worst itch score of ≥7 in the 7 days prior to run-in visit and in the 7 days prior to Day 1 on the WI-NRS.\n* Participants scored \"severe\" in the PGIS of pruritus on Day 1.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.\n* Patients with active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis, unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent.\n* Diagnosed with, suspected of, or at high risk of endoparasitic infection, and\u002For use of antiparasitic drug within 2 weeks before the screening visit.\n* HIV infection.\n* Severe renal failure (dialysis).\n* Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the run-in visit.\n* Known or suspected immunodeficiency.\n* Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin.\n* History of hypersensitivity or intolerance to non-sedative antihistamines.\n* Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","90 Years",{"count":105,"type":21},284,[107],"PHASE3","The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO.\n\nThis is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A.\n\nFor both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (worst-itch numerical rating scale \\[WI-NRS ≥7) will enter a 4-week run-in period and will be treated with a non-sedative antihistamine and an emollient (moisturizer). Participants with severe pruritus (WI-NRS ≥7) at baseline will be randomized (1:1) to be treated for 24 weeks with either dupilumab or matching placebo in addition to their non-sedative antihistamine and emollient regimen. The treatment period for both study A and B will be followed by a 12-week follow-up period.",[26],"2026-06-05",{"date":112,"type":33},"2026-06-08",{"date":114,"type":33},"2022-02-15",{"date":116,"type":21},"2027-08-25",{"name":118,"class":69},"Sanofi",92,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":52,"phases":130,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":41},"100626188","phase-4-methotrexate-versus-apremilast-for-pruritus-in-psoriasis-100626188","NCT07432386","Methotrexate Versus Apremilast for Pruritus in Psoriasis","Comparison of Efficacy of Methotrexate Versus Apremilast in the Treatment of Pruritus in Psoriasis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male and female patients aged 18 to 65 years.\n* Clinically diagnosed cases of psoriasis.\n* Patients experiencing pruritus associated with psoriasis.\n* Patients willing to participate and provide written informed consent.\n* Patients able to comply with study protocol and follow-up visits.\n\nExclusion Criteria:\n\n* \\- Pregnant or lactating women.\n* Patients with severe hepatic or renal impairment.\n* Patients with known hypersensitivity to Methotrexate or Apremilast.\n* Patients currently receiving systemic therapy for psoriasis within the last 4 weeks.\n* Patients with active infections, including tuberculosis.\n* Patients with malignancy.\n* Patients with significant hematological abnormalities.\n* Patients unwilling to provide informed consent.","65 Years",{"count":129,"type":21},80,[131],"PHASE4","This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.",[134,26],"Psoriasis",[136],"Methotrexate Apremilast Randomized Controlled Trial Dermatology Life Quality Index DLQI Psoriasis Treatment Itch Severity Numerical Rating Scale","2026-05-13",{"date":139,"type":33},"2026-05-15",{"date":141,"type":21},"2026-05-14",{"date":143,"type":21},"2026-10-14",{"name":145,"class":40},"Zarmeen Khawar",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100550402","drug-induced-liver-injury-itching-study-100550402","NCT06446609","Drug-induced Liver Injury: Itching Study","Understanding the Natural History and Impact of Itching (Pruritus) in Patients With Drug-induced Liver Injury (DILI)","Inclusion Criteria:\n\n* Age ≥18 (no upper age limit) and able to give informed written consent\n* Exposure to potential causal agent and diagnosed with suspected acute DILI defined as meeting one of the following analytical thresholds at enrolment (visit 1):\n\n  * alanine transaminase (ALT) ≥5 times upper limit of normal (ULN) or\n  * alkaline phosphatase ≥2 times ULN or\n  * ALT ≥3 times ULN plus total bilirubin \\>2 times ULN\n\nResults from clinical test samples collected within 36h of visit will be acceptable (as DILI is an acute event, patients are expected to recover or deteriorate quickly so enrolment aligned with diagnostic tests is necessary).\n\nExclusion Criteria:\n\n* Patients with comorbidities of eczema and urticaria associated with pruritus\n* Patients with existing diagnosis of blood-borne viral hepatitis infection (Hepatitis B\u002FC\u002FE)",{"count":154,"type":21},50,"Idiosyncratic drug-induced liver injury (DILI) is an unpredictable adverse hepatic reaction to a medication used in its therapeutic dose. DILI is the second most common cause of itching in adult Hepatology after biliary obstruction. In particular cholestatic or mixed pattern types of DILI (in which bile flow from the liver is impaired) are associated with long-lasting effects as well as reduced quality of life. There is therefore an urgent need to determine the incidence and natural history of itching in DILI and establish a network of centres that will form a basis for a clinical trial to investigate a novel intervention to treat these.",[157,26],"Drug Induced Liver Injury","2026-04-24",{"date":160,"type":33},"2026-04-30",{"date":162,"type":33},"2025-06-30",{"date":164,"type":21},"2028-05",{"name":166,"class":40},"University of Nottingham",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":52,"phases":175,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":41},"100627598","early-phase-1-assessing-the-efficacy-and-safety-of-photobiomodulation-for-the-treatment-of-pruritus-100627598","NCT07450716","Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus","Inclusion Criteria:\n\n1. Participant is an adult at least 18 years-of-age.\n2. Participant meets the criteria for acute or chronic itch as defined below:\n\n   1. Acute itch lasting less than 6 weeks.\n   2. Chronic itch lasting more than 6 weeks.\n3. Participant is able and willing to comply with all the study visit, treatment, and evaluation schedules and requirements.\n4. Participant can understand and provide written informed consent.\n5. Participant does not have any concurrent injury or wound in their target treatment area.\n6. Participant is either untreated for their pruritus, or if on therapy, must have been maintained on a stable regimen of antipruritic treatments for the past 14 days prior to enrollment.\n7. Participant has mild, moderate, or severe pruritus as defined below:\n\n   1. Mild: average score \\\u003C4 on the PP-NRS during the week before baseline.\n   2. Moderate: average score 4-7 on the PP-NRS during the week before baseline.\n   3. Severe: average score of \\> 7 on the PP-NRS during the week before baseline.\n8. Participants must have comparable pruritus affecting symmetrical or corresponding areas on both sides of their body to allow for the split-body study design.\n\nExclusion Criteria:\n\n1. Participant has any active internal or cutaneous malignancy located within the proposed treatment area.\n2. Participant cannot provide informed consent or adhere to study schedule.\n3. Participant is actively tanning during the study course.\n4. Participant has melasma or another condition exacerbated by heat.\n5. Participant is on a photosensitizing medication, such as doxycycline or has a photosensitizing condition.\n6. Patient is currently pregnant or breastfeeding.\n7. Participant has psychogenic pruritus, a diagnosed skin-picking (excoriation) disorder, or any other current psychiatric condition that, in the investigator's judgment, could interfere with informed consent, adherence to the study protocol, or safe participation.\n8. Participant has any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this study.",{"count":174,"type":21},20,[176],"EARLY_PHASE1","This study is designed to evaluate the safety and effectiveness of a low-level near-infrared LED light device for relieving itch. The device is non-invasive, does not break the skin, and does not produce heat. Near-infrared light has been used in other medical settings and is known to interact with skin and nerve pathways. In this study, researchers are examining whether this light can be safely applied to the skin and whether it may help reduce itch by affecting signals involved in itch sensation.",[26],"2026-04-09",{"date":181,"type":33},"2026-04-13",{"date":183,"type":21},"2026-04",{"date":185,"type":21},"2026-12",{"name":187,"class":40},"Massachusetts General Hospital",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":52,"phases":198,"briefSummary":200,"conditions":201,"keywords":212,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":225,"locationsCount":41},"100617334","vr-pmr-for-post-burn-symptoms-100617334","NCT07317271","VR-PMR for Post-Burn Symptoms","Virtual Reality-Enhanced Progressive Muscle Relaxation for Symptom Management in Burn Survivors","VIBE","Inclusion criteria are:\n\n* ≥18 years old;\n* sustained a burn injury in the last 6 months or longer;\n* Score high on at least one of the following: Insomnia severity index (ISI) score of ≥8, Brief Pain Inventory Short Form (BPI-SF) Pain severity score of ≥3, or PROMIS Itch Severity of ≥55;\n* own a smartphone or computer with reliable internet connection for online visits and survey completion;\n* able to comfortably wear goggles or headsets on face as determined by self-report.\n\nExclusion criteria:\n\n* Cognitive impairment (Mini Mental Status Exam (MMSE) \\\u003C 25);\n* history of motion sickness, photosensitivity, photoinduced seizures, and claustrophobia as determined by self-report;\n* uncorrected visual or hearing impairments as determined by self-report;\n* non-English speaker.",{"count":197,"type":21},34,[199],"NA","The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors.\n\nThe main questions it aims to answer are:\n\n* Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR?\n* Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors?\n\nResearchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors.\n\nParticipants will:\n\n* Complete home-based sessions of VR-enhanced PMR\n* Complete home-based sessions of standard PMR\n* Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study\n* Use VR equipment provided for the intervention period (during the VR-PMR arm)",[202,203,204,205,206,207,208,209,26,210,211],"Burn","Chronic Pain Following Thermal Burn Injury","Non-Pharmacological Interventions","Virtual Reality","Sleep Disturbance","Anxiety","Depressive Symptoms","Fatigue Symptom","Burn Injury","Progressive Muscle Relaxation",[205,213,211,214,215,28,216,217,218,210],"Burn Survivors","Chronic Symptom Management","Pain","Sleep","Fatigue","Burns","2026-03-03",{"date":221,"type":33},"2026-03-05",{"date":223,"type":33},"2026-02-27",{"date":185,"type":21},{"name":226,"class":40},"Johns Hopkins University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":52,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100573805","cervical-traction-to-reduce-gabaergic-medication-use-for-neuropathic-itch-100573805","NCT06751056","Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch","Neck Traction to Reduce Gabaergic Medication Use for Neuropathic Itch- A Pilot Study","Inclusion Criteria\n\n* Persons with scalp, arm, and upper back pruritus without primary skin lesions.\n* Persons 18 or older.\n* Person on a stable dosage of gabapentin or pregabalin over the preceding 4 week period.\n* Persons willing and able to comply with clinic visits and study-related procedures.\n* Persons willing and able to understand and complete study-related questionnaires.\n* Persons willing and able to provide voluntary signed informed consent.\n\nExclusion Criteria\n\n* Primary skin lesions driving scalp, arm, or upper back pruritus.\n* A history of spinal surgery or other conditions (acute or traumatic spinal injury, spinal instability, spinal fracture, rheumatoid arthritis, metastatic disease to the spine, spinal cord compression, active infections of the head and neck) that would make neck traction contraindicated.\n* Unable to comfortably lay down on the floor and get back up without assistance.\n* Medical conditions in which gabapentin and\u002For pregabalin is contraindicated.\n* Current enrollment in physical therapy with exercises addressing the cervical spine.\n* Planned or anticipated use of any prohibited medications or procedures during study treatment.\n* Presence of skin comorbidities that may interfere with study assessments.\n* Currently pregnant or breastfeeding or plans to become pregnant or breastfeed during the participation in the study. Persons of childbearing age who are not on reliable contraception will be considered on a case-by-case basis.\n\n  o Participants of childbearing age who are not on reliable contraception (hormonal contraceptive pills, patch, or ring, intrauterine device, subdermal hormonal implant, tubal ligation, depot medroxyprogesterone injections) will be required to complete monthly urine pregnancy tests.\n* Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study. Examples include, but are not limited to, a short life expectancy, persons with uncontrolled diabetes (HbA1c ≥ 9%), cardiovascular conditions (e.g. stage III or IV cardiac failure), severe renal conditions (e.g. patients on dialysis), debilitating neurological conditions (e.g. demyelinating diseases), active major autoimmune diseases (e.g. lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), or other severe endocrinological, gastrointestinal, hepatobiliary, metabolic, pulmonary, or lymphatic diseases. The specific justification for persons excluded under this criterion will be noted in study documents.\n* Any other medical or psychological condition (including relevant laboratory abnormalities at screening) that, in the opinion of the investigator, may suggest a new and\u002For insufficiently understood disease, may present an unreasonable risk to the study patient as a result of his\u002Fher participation in this clinical trial, may make participation unreliable, or may interfere with study assessments. The specific justification for persons excluded under this criterion will be noted in study documents.",{"count":235,"type":21},12,[199],"The purpose of this study is to determine if cervical traction is an effective treatment to reduce GABAergic medication use for scalp, arm, and upper back neuropathic itch.",[26],"2025-09-03",{"date":241,"type":33},"2025-09-09",{"date":243,"type":33},"2025-06-01",{"date":245,"type":21},"2027-01-10",{"name":247,"class":40},"Mayo Clinic",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":255,"enrollmentInfo":256,"targetDuration":4,"studyType":52,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":4},"100572457","phase-2-th104-for-the-treatment-of-pruritus-in-primary-biliary-cholangitis-100572457","NCT06733519","TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis","Evaluation of TH104 for Moderate to Severe Pruritus in Primary Biliary Cholangitis: a Double-blind, Randomized, Placebo-controlled, Phase 2a Study","Inclusion Criteria:\n\n1. Men or women aged 18 to 75 years, inclusive, at the time of signing the informed consent form.\n2. Diagnosis of PBC, as demonstrated by the participant presenting with at least 2 of the following criteria at the Screening Visit:\n\n   1. history of sustained increased alkaline phosphatase (ALP) levels first recognized at least 6 months prior to the Screening Visit\n   2. positive antimitochondrial antibodies (AMA) titer (\\>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay \\[ELISA\\])\n   3. PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)\n   4. liver biopsy consistent with PBC Note: Participants with compensated cirrhosis will be eligible for enrollment only after the DSMB reviewed the safety and tolerability of TH104 in the first 10 non-cirrhotic participants.\n3. Screening ALP value below 10 × upper limit of normal (ULN).\n4. Participants taking the following drugs may be enrolled to the study, as long as they are on stable doses for \\> 12 weeks prior to the Screening Visit; Ursodeoxycholic acid (UDCA) Obeticholic acid Elafibranor Seladelpar Fibrates such as bezafibrate and fenofibrate Cholestyramine Antihistamines\n5. Symptoms of pruritus - rated as NRS \\> 4 for worst daily score:\n\n   * At screening AND\n   * At least on 4 days during the 1-week baseline observation period.\n6. A woman is eligible to participate if she is not breast-feeding or pregnant, as confirmed by a negative serum human chorionic gonadotrophin (hCG) test or at least one of the following conditions applies:\n\n   1. Non-reproductive potential defined as pre-menopausal with a documented tubal ligation or hysterectomy; or post-menopausal defined as 12 months of spontaneous amenorrhea \\[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \\>40 mIU\u002FmL and estradiol \\\u003C40 pg\u002FmL (\\\u003C147 pmol\u002FL) is confirmatory\\]. Women on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods along with either a second form of highly effective contraception or barrier protection (condoms with spermicide) if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment;\n   2. Reproductive potential and agrees to follow one of the contraception options methods for the specified duration of time.\n\n   For men participating in the study and having a female partner - birth control methods described above will have to be used throughout the study.\n7. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n\nExclusion Criteria:\n\n1. Screening total bilirubin \\>2.0 x ULN.\n2. Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>4 x ULN.\n3. Screening serum creatinine \\>2.5 mg\u002FdL (221 µmol\u002FL).\n4. History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).\n5. History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease, definite autoimmune hepatitis or biopsy-proven non-alcoholic steatohepatitis (NASH\u002FMASH\u002FMAFLD).\n6. Thyroid stimulating hormone (TSH) out of normal ranges.\n7. Administration of the following drugs at any time during the 3 months prior to the Screening Visit: colchicine, methotrexate, azathioprine, opioids, opioids antagonists, or systemic corticosteroids.\n8. Current or chronic history of inflammatory bowel disease, chronic diarrhea, Crohn's disease, or diarrhea related to malabsorption syndromes.\n9. Based on averaged corrected QT interval (QTc) values of triplicate electrocardiograms (ECGs) obtained at least 5 minutes apart: QTc ≥450 msec; or QTc ≥480 msec in participants with Bundle Branch Block.\n10. History of sensitivity to any of the study medications (or components thereof) or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.\n11. History of regular alcohol consumption within 6 months of the Screening Visit defined as an average weekly intake of \\>21 units for men or \\>14 units for women. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.\n12. A positive screening drug\u002Falcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines.\n13. Where participation in the study would result in blood in blood sampling in excess of 500 mL within a 56-day period.\n14. Treatment with sertraline and\u002For rifampicin \\\u003C 4 weeks prior to the Screening Visit.\n15. Clinically significant abnormality of the buccal mucosa which could impact drug absorption.\n16. Participation in a clinical trial with an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer) before the first dosing in this study.\n17. Decompensated liver disease (encephalopathy, ascites, or Child Pugh score \\> 10 points). Participants with compensated cirrhosis will be eligible for enrollment after the DSMB reviewed the safety and tolerability of TH104 for the first 10 non-cirrhotic participants).","75 Years",{"count":257,"type":21},40,[54],"A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.",[26,261],"Primary Biliary Cholangitis","2025-09-02",{"date":241,"type":33},{"date":265,"type":21},"2026-06-01",{"date":267,"type":21},"2027-06-01",{"name":269,"class":69},"Tharimmune Inc",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":277,"sex":16,"minAge":17,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":52,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100587165","a-clinical-study-to-assess-the-safety-and-effectiveness-of-utixira-lotion-and-utixira-tablet-in-healthy-adult-human-subjects-with-dry-or-sensitive-skin-prone-to-mild-to-moderate-pruritus-and-urticaria-100587165","NCT06924840","A Clinical Study to Assess the Safety and Effectiveness of Utixira Lotion and Utixira Tablet in Healthy Adult Human Subjects With Dry or Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria","A Clinical Evaluation of the Safety, In-Use Tolerability, and Efficacy of the Utixira Lotion and Utixira Tablet Combination Regimen in Healthy Adults With Dry, Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria","Inclusion Criteria:\n\n* Age: 18 to 55 years (both inclusive) at the time of consent.\n* Sex: Healthy male and non-pregnant\u002Fnon-lactating females.\n* Females of childbearing potential must have a self-reported negative pregnancy test.\n* Subject are generally in good health.\n* Subject with dry or sensitive skin at a time of screening. (Dermatological Assessment)\n* Subjects having pruritus or urticaria at a time of screening.\n* Subjects application site must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds.\n* Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n* If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n* Subjects are willing to give written informed consent and are willing to come for regular follow up.\n* Subjects who commit not to use medicated skincare product other than the test product for the entire duration of the study.\n* Subject who have not participated in a similar investigation in the past three months.\n* Willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* History of any dermatological condition of the skin diseases.\n* Subject with present condition of allergic response to any cosmetic product.\n* Subject having allergic response to the ink.\n* Presence of any broken, chapped, cut, irritated, or scraped skin at the application site.\n* Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.\n* Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal treatment.\n\nSubjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study.\n\n* History of alcohol or drug addiction.\n* Subjects using other marketed products during the study period.\n* Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.\n* Pregnant or breastfeeding or planning to become pregnant during the study period.\n* History of chronic illness which may influence the cutaneous state.\n* Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.",true,"55 Years",{"count":280,"type":21},32,[199],"This exploratory, prospective, open-label, single-centre, safety, efficacy and in-use tolerability study of the Utixira Lotion + Utixira Lotion as regimen in healthy adult human subjects with dry or sensitive skin and prone to mild to moderate pruritus or urticaria",[284,285,26,286],"Dry Skin","Urticaria","Sensitive","2025-04-15",{"date":289,"type":33},"2025-04-18",{"date":291,"type":21},"2025-05-15",{"date":293,"type":21},"2025-06-15",{"name":295,"class":40},"SAVA Healthcare Limited",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":52,"phases":305,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100587648","phase-1-aprepitant-in-the-management-of-immune-checkpoint-inhibitors-pruritus-in-solid-cancer-patients-100587648","NCT06931119","Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients","Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus: Pilot Study in Solid Cancer Patients","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed solid tumor (e.g., melanoma, RCC, NSCLC).\n* Currently receiving ICIs (such as but not limited to nivolumab, pembrolizumab, ipilimumab)\n* Pruritus that is either:\n* Refractory: Persistent pruritus despite standard treatment (e.g., antihistamines, corticosteroids).\n* New-onset: Developing after initiation of ICIs or targeted therapies.\n* ECOG performance status 0-2.\n* Willingness to comply with study procedures and provide informed consent.\n\nExclusion Criteria:\n\n* History of severe allergic reactions to Aprepitant.\n* Uncontrolled or severe dermatologic conditions unrelated to cancer therapy.\n* Use of NK1R antagonists within 4 weeks before study entry.\n* Concurrent use of medications that strongly interact with Aprepitant.\n* Concurrent use of medications that may influence pruritus manifestation (e.g steroids or antihistamines) . Note, Regular treatment with such medications prior to the appearance of pruritus, and or pruritus appearing despite such regular treatment, will not disqualify you from participating in the study\n* Uncontrolled infection or significant comorbidities.\n* Pregnant or breastfeeding women.",{"count":304,"type":21},30,[306],"PHASE1","Pruritus, commonly known as itching, is an unpleasant sensation that triggers the urge to scratch, which may provide temporary relief. Pruritus can be intermittent or persistent, localized or widespread, and may be associated with medication use. Chronic pruritus, defined as lasting more than six weeks, can significantly affect sleep and quality of life.\n\nDermatologic toxicities are among the most common immune-related adverse events (irAEs), reported in 43-45% of patients receiving ipilimumab and approximately 34% of those treated with nivolumab or pembrolizumab. Combination therapies (ipilimumab+ nivolumab or pembrolizumab) tend to elevate the incidence of potential irAEs to 41%. These toxicities typically emerge within the first few weeks of treatment, though delayed-onset cases have been documented. Cutaneous irAEs occur more rapidly in patients receiving combination therapy compared to anti-PD1 monotherapy.\n\nPruritus is one of the most frequently observed cutaneous irAEs. Current treatments for pruritus are often inadequate, leaving many patients suffering from persistent and debilitating symptoms. Despite available therapies, a significant number of individuals continue to experience chronic itch that negatively impacts their quality of life. Substance P (SP) functions as a neurotransmitter and neuromodulator in the central and peripheral nervous systems of mammals. It is produced by both neuronal and non-neuronal cells and plays a role in various physiological responses, including nausea, depression, vomiting, pain, neurogenic inflammation, and, more recently, pruritus. SP exerts its biological effects primarily through neurokinin receptors (NKRs), also known as tachykinin receptors. When SP binds to NK1R in the skin, it triggers mast cell degranulation, leading to the release of pruritogenic and proinflammatory mediators such as histamine, interferon-γ, leukotriene B4, vascular endothelial growth factor (VEGF), and nerve growth factor (NGF). This results in vasodilation and neurogenic inflammation, manifesting clinically as pruritus, erythema, and edema. NK1R antagonists are a class of drugs with antiemetic, antidepressant, anxiolytic, and antipruritic properties, though they have not been effective as analgesics in humans. These drugs act centrally by crossing the blood-brain barrier and selectively blocking NK1R activation by SP in the central nervous system, particularly in vomiting centers. Aprepitant has also demonstrated efficacy in treating pruritus induced by anticancer therapies.\n\nThis study is a pilot, single-center open label study evaluating the safety and efficacy of single course of EMEND® (aprepitant) capsules (80mg +125mg) in treating pruritus (new onset and\u002For refractory) induced by immune checkpoint inhibitors in patients with solid tumors.",[26],[310],"pruritus, immune checkpoint inhibitors","2025-04-08",{"date":313,"type":33},"2025-04-17",{"date":315,"type":21},"2025-05-30",{"date":317,"type":21},"2026-12-30",{"name":319,"class":40},"Rabin Medical Center",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":52,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":41},"100576630","reducing-itch-with-hypnosis-and-virtual-reality-100576630","NCT06787794","Reducing Itch With Hypnosis and Virtual Reality","The Effectiveness of Virtual Reality-assisted Hypnosis in Reducing Itch: a Proof-of-concept Study","VRITCH","Inclusion Criteria:\n\n* Participants must be adults (aged 18-80 years)\n* Participants must have been suffering from chronic pruritus of any origin for at least 1 year prior to inclusion in this study\n* Participants must have been seen by a physician for the itch\n* Participants must experience psychological and\u002For functional impairment due to the itch despite standard medical treatment.\n* Participants must speak and understand Dutch and be able to complete questionnaires.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities irrelated to their itch condition such as psychosis or severe clinical depression or anxiety disorder (anxiety and depressive symptoms in itself are common in individuals with chronic symptoms and therefore no reason for exclusion);\n* History of seizures;\n* History of severe migraine;\n* Severe susceptibility to motion sickness;\n* Balance problems;\n* Face, head, or neck injury;\n* Visual or audiological impairment;\n* Pacemaker, defibrillator and\u002For other electronic (implantable) device of vital importance;\n* Pregnancy;\n* Lactation;\n* Participation in another interventional itch study.","80 Years",{"count":304,"type":21},[199],"Chronic itch is a disabling condition with currently limited treatment options. Virtual reality (VR) is a relatively new approach that provides immersion in another environment and has been shown to have a temporary itch mitigating potential. Hypnosis, which is a state of relaxation, has been successfully applied with more long-term treatment effects in the specific case of itch as a result of severe atopic dermatitis. However, hypnosis tends to depend on an individual's susceptibility, or ease, to come into a hypnotic state. A combination of VR and hypnosis (VRH) has been put forward since it may combine the longer lasting effects of hypnosis with VR making the hypnosis more accessible by facilitating imagination. Even though VRH is a promising avenue, it has never been investigated in the context of itch. In this randomized controlled trial, comparing a VRH treatment with a waiting list control group after 6 sessions and at follow-up, it is aimed to assess the effectiveness of VRH in reducing itch along with its psychological burden in adult individuals with therapy-resistant disabling itch.",[333,26],"ITCH",[27,335,336,337,338,339,340],"Chronic Itch","Therapy resistant","Virtual Reality (VR)","Hypnosis","Relaxation","Distraction","2025-03-24",{"date":343,"type":33},"2025-03-25",{"date":345,"type":33},"2025-01-31",{"date":347,"type":21},"2026-12-31",{"name":349,"class":40},"Universiteit Leiden",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":357,"phases":4,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":364,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":368,"locationsCount":4},"100473690","linerixibat-compassionate-use-for-cholestatic-pruritus-adult-patients-with-primary-biliary-cholangitis-pbc-100473690","NCT05448170","Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)","Linerixibat Compassionate Use for Cholestatic Pruritus in Adult Patients With Primary Biliary Cholangitis","Inclusion Criteria:\n\n* Participants with cholestatic pruritus associated to PBC identified by their healthcare provider as being at high risk of a significant clinical event as a result of their pruritus.\n* Male and female \\>= 18 years of age.\n* Participants for whom all available pharmaceutical treatments for cholestatic pruritus in PBC have been unsuccessful or are considered to not be appropriate.\n* Contraceptive\u002FBarrier Requirements (applicable for female participants only): A female participant is eligible if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n  1. Is not a woman of childbearing potential (WOCBP) OR\n  2. Is a WOCBP and using an acceptable contraceptive method during the treatment with linerixibat and for at least 4 weeks after the last dose of linerixibat.\n\nExclusion Criteria:\n\n* Advanced chronic liver disease (e.g. cirrhosis Child-Pugh C) or presence of hepatic decompensation (e.g. variceal bleeding, encephalopathy).\n* Use of obeticholic acid or other IBAT inhibitor.","EXPANDED_ACCESS","The goal of this compassionate use program is to provide a mechanism to supply linerixibat, on an individual named patient basis. This program is for treatment of individuals who have cholestatic pruritus associated with PBC who are deemed at high risk of a significant clinical event as a result of their pruritus and for whom all available pharmaceutical treatment options for cholestatic pruritus have been unsuccessful or are considered to not be appropriate.",[26],[361,362,261,363],"Linerixibat","Individual Patient Compassionate Use","Ileal bile acid transporter (IBAT) inhibitor","AVAILABLE","2025-02-25",{"date":367,"type":33},"2025-02-27",{"name":369,"class":69},"GlaxoSmithKline",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":16,"minAge":378,"maxAge":4,"enrollmentInfo":379,"targetDuration":381,"studyType":23,"phases":4,"briefSummary":382,"conditions":383,"keywords":384,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":41},"100525374","swiss-itch-registry-100525374","NCT06120907","Swiss Itch Registry","Swiss Itch Registry (SWITCHR) - A Prospective Registry to Collect Data of Patients With Chronic Pruritus","SWITCHR","Inclusion Criteria:\n\n* Age ≥ 14 years.\n* Written informed consent of the patient.\n* Diagnosis of CP irrespective of the International Forum for the Study of Itch (IFSI) group (I-III) and\u002For underlying cause (according to the judgment of the investigator).\n* A Numerical Rating Scale (NRS) score of min. ≥ 4 within the last 7 days.\n* Sufficient language skills (in the languages which the patient information and the consent form is available) to provide informed consent.\n\nExclusion Criteria:\n\n* Any medical or psychological condition in the treating physician's opinion, which may prevent the patient in registry participation\n* Lack of informed consent for registry participation.\n* Refusal to complete Patient Reported Outcomes (PROs)","14 Years",{"count":380,"type":21},100,"60 Months","This project is to develop a national registry for CP patients. Patients admitted to this registry will be examined and documented with PROs, physician-based assessments, blood tests, 3D photodocumentation and, if indicated, by skin biopsies, neurophysiological testing and radiological imaging at defined timepoints. The data collection will allow deepened insights into patient needs, different mechanisms and courses of pruritic conditions, treatment outcomes and treatment-related safety issues. In addition, the collection of clinical, biological and image-based data may be used for retrospective analyses.",[26],[28,385],"Chronic pruritus (CP)","2024-12-12",{"date":388,"type":33},"2024-12-13",{"date":390,"type":33},"2023-10-18",{"date":392,"type":21},"2033-10",{"name":394,"class":40},"University Hospital, Basel, Switzerland",{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":16,"minAge":403,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":52,"phases":406,"briefSummary":407,"conditions":408,"keywords":410,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":41},"100477732","meditation-in-inflammatory-dermatosis-100477732","NCT05500794","Meditation in Inflammatory Dermatosis","Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis)","MediDermIn","Inclusion Criteria:\n\n* Patient aged 18 years old or older\n* With health insurance coverage\n* Significant pruritus defined by a Visual Analogical Scale (VAS) pruritus ≥ 4\n* Patient with plaque psoriasis\n\n  * Without joint involvement\n  * Mild to moderate severity (PASI\\>10)\n  * DLQI \\> 10\n\nOR Patient with atopic dermatitis:\n\n* Mild to moderate severity (SCORAD\\>10)\n* DLQI \\> 10\n* Diagnosis according to Hanifin and Raijka criteria\n\n  * Patient in a stable psychological state\n  * French langage spoken\n\nExclusion Criteria :\n\n* Current systemic treatment or treatment discontinued within the last month\n* Psychiatric illnesses diagnosed according to the DSM-5 or ICD-10 international criteria of psychotic disorder, severe anxiety disorder, depressive disorder with a current depressive episode of severe intensity, bipolar disorder with a current depressive or manic episode\n* Taking psychotropic or neuroleptic treatments\n* Participation in another interventional research study or being in the exclusion period at the end of a previous study, if applicable\n* Patient under AME","18 Days",{"count":405,"type":21},72,[199],"Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world. Although the physiopathological mechanisms are not yet clearly defined, these inflammatory dermatoses involve an interaction between the immune system and the epidermal cells, severe skin inflammation and often very intense pruritus. The objectives of an effective management should be to treat lesions in order to reduce them, but also to reduce itching and allow the patients to accept and cope with their pathology, without neglecting an improvement in the \"Dermatology Life Quality Index\" (DLQI) and in the psychological state, sometimes depressive, of the patient. Itching is defined as \"a feeling that needs to be scratched urgently\" and can cause significant distress along with pain. It severely impacts the quality of life and the quality of sleep. Chronic itching is associated with increased stress, anxiety, and other mood disorders. In turn, stress and anxiety exacerbate the itching, leading to a vicious cycle of pruritus - scratching that affects patient behavior (excessive scratching) and worsens disease prognosis and quality of life. Much research over the past few decades has demonstrated the effect of mindfulness meditation on emotional and cognitive responsiveness, cognitive flexibility, rumination, self-compassion and mindfulness, but also on acute pain, anxiety, stress, depression, cardiovascular disease, eating disorders, cancer and cognitive loss with age. Several studies have shown the impact of mindfulness on brain function and immunity, with evidence for the association between mindfulness and changes in the levels of markers characteristic of immune system activity and inflammation, known to be increased in psoriasis or atopic dermatitis. The objective is to evaluate the effect of mental training in the regulation of stress and emotions through mindfulness meditation in patients with moderate, itchy atopic dermatitis or psoriasis, not treated with systemic agents (e.g.: biotherapies). This project is based on the premise that mental training in the regulation of stress and emotions through meditation would reduce the effects of the infernal itch-scratch cycle, alleviating pruritus, thus improving the well-being and mental health of patients while reducing their inflammatory skin lesions and limiting the appearance of new lesions.",[409,134,26],"Atopic Dermatitis",[411,412,134,409,26,413],"Mindfulness","Based Stress Reduction","Inflammatory Cytokines","2024-09-13",{"date":416,"type":33},"2024-09-19",{"date":418,"type":33},"2022-11-15",{"date":139,"type":21},{"name":421,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":277,"sex":16,"minAge":49,"maxAge":255,"enrollmentInfo":429,"targetDuration":4,"studyType":52,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":41},"100553642","the-efficacy-of-3-kanuka-oil-versus-1-hydrocortisone-cream-in-patients-with-atopic-dermatitis-100553642","NCT06488742","The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis","Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in the Treatment of Patients With Mild Atopic Dermatitis","Inclusion Criteria:\n\n* age greater than 12 years, diagnosis of atopic dermatitis for longer than 2 years, investigator's static global assessment score of either 2 or 3, and initial worst itch numerical rating scale (WI-NRS) for itch greater than 4.\n\nExclusion Criteria:\n\n* the use of topical or systemic corticosteroids within 28 days of entering the study, the use of any other non-emollient therapy within 28 days of entering the study,nursing, and pregnancy",{"count":430,"type":21},60,[199],"Atopic dermatitis is a common disease affecting millions worldwide. A common associated symptom in this population is pruritus. We seek to investigate the use of an natural, over-the-counter cosmeceutical to help this population",[434,26],"Dermatitis, Atopic","2024-06-28",{"date":437,"type":33},"2024-07-05",{"date":439,"type":33},"2023-11-01",{"date":441,"type":21},"2025-03-20",{"name":443,"class":69},"Nexgen Dermatologics, Inc."]